In a 39‑week gravida 2, para 1 patient presenting with contractions and new moderate vaginal bleeding but stable vital signs, what is the next step in management: administer oxytocin, perform a nitrazine test, obtain a bedside transabdominal pelvic ultrasound, or conduct a sterile vaginal examination?

Management of Third-Trimester Vaginal Bleeding at 39 Weeks

Perform a bedside transabdominal pelvic ultrasound immediately—do NOT perform a digital vaginal examination until placenta previa, low-lying placenta, and vasa previa are excluded by imaging, as a blind exam can trigger catastrophic hemorrhage. 1

Immediate Diagnostic Approach

The critical first step in managing new moderate vaginal bleeding at term is imaging before any digital examination:

• Transabdominal ultrasound is the first-line imaging modality for any pregnant patient presenting with second- or third-trimester vaginal bleeding 2. This allows rapid assessment of placental location, fetal status, and potential causes of bleeding without risk of provoking hemorrhage.

• Digital pelvic examination must be avoided until placenta previa, low-lying placenta, and vasa previa are definitively excluded by imaging 1. A blind digital exam in the presence of placenta previa can precipitate life-threatening maternal hemorrhage and is contraindicated.

• Transvaginal ultrasound should follow if transabdominal imaging is inconclusive or to confirm placental location and measure the distance between the placental edge and internal cervical os 3, 1. Despite historical concerns, transvaginal ultrasound is both accurate and safe, providing superior visualization compared to transabdominal or transperineal approaches 3, 1.

Why the Other Options Are Incorrect

Oxytocin administration is contraindicated at this stage 4:

• Oxytocin is used for labor induction/augmentation or postpartum hemorrhage prevention—not for diagnostic evaluation of antepartum bleeding 4
• The FDA label explicitly warns against oxytocin use in conditions like "previous major surgery on the cervix or uterus" and situations where the cause of bleeding is unknown 4
• Administering oxytocin before excluding placenta previa could worsen hemorrhage and is dangerous

Nitrazine paper test is used to detect ruptured membranes (amniotic fluid has alkaline pH), not to evaluate vaginal bleeding 2. This test is irrelevant to the differential diagnosis of antepartum hemorrhage and would delay appropriate imaging.

Sterile vaginal examination poses the same catastrophic risk as digital examination when placenta previa has not been excluded 1. Even a "sterile" speculum exam should be deferred until imaging rules out placental causes of bleeding.

Subsequent Management After Imaging

Once ultrasound excludes placenta previa and other placental abnormalities:

• Evaluate for placental abruption using transabdominal ultrasound, though sensitivity is limited; identification of abruption correlates with worse perinatal outcomes 2

• Assess for labor by evaluating contraction pattern, cervical changes (via ultrasound if exam still deferred), and fetal status 2

• Consider other causes including bloody show from cervical change, cervical lesions, or vasa previa (which requires color Doppler assessment) 2

Key Clinical Pitfalls

The most dangerous error in this scenario is performing any form of vaginal examination before imaging. This single mistake can convert a stable patient with moderate bleeding into a life-threatening hemorrhage requiring emergency cesarean delivery and massive transfusion. The ACR guidelines explicitly state this as expert consensus based on the catastrophic consequences observed when this principle is violated 1.

At 39 weeks with contractions, the differential includes normal labor with bloody show, placental abruption, placenta previa, or vasa previa. Only imaging can safely distinguish these, and only after exclusion of placental causes should direct cervical assessment be considered 2, 1.